Share on StockTwits

Galena Biopharma (NASDAQ:GALE) issued its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.08, Analyst Ratings Network reports. The company had revenue of $2.30 million for the quarter, compared to the consensus estimate of $2.99 million.

Galena Biopharma (NASDAQ:GALE) traded down 1.29% during mid-day trading on Monday, hitting $3.06. 1,969,422 shares of the company’s stock traded hands. Galena Biopharma has a 52 week low of $1.66 and a 52 week high of $7.77. The stock’s 50-day moving average is $2.93 and its 200-day moving average is $3.0. The company’s market cap is $361.2 million.

On a related note, analysts at Roth Capital raised their price target on shares of Galena Biopharma to $8.00 in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $7.00.

Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.